Cancer therapy finds a solid target

CMAJ. Canadian Medical Association Journal

Volumn 173, Issue 3, 2005, Pages 246-

  Secko, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; STA 21; STAT3 INHIBITOR; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; GENETIC TRANSCRIPTION; LYMPHOMA CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; SHORT SURVEY; SOLID TUMOR; TRANSCRIPTION REGULATION;

EID: 23244441405     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.050793     Document Type: Short Survey

References (3)

1. Yu H, Jove R. The STATs of cancer - new molecular targets come of age [review]. Nat Rev Cancer 2004;4(2): 97-105.
2. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005;11 (6):623-9.
3. Song H, Wang R, Wang S, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A 2005;102(13):4700-5.